- Home
- ACRV vs ETON Comparison
ACRV vs ETON Comparison
Compare ACRV & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ETON
- Stock Information
- Founded
- ACRV 2018
- ETON 2017
- Country
- ACRV United States
- ETON United States
- Employees
- ACRV N/A
- ETON N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- ETON Health Care
- Exchange
- ACRV Nasdaq
- ETON Nasdaq
- Market Cap
- ACRV 225.8M
- ETON 199.5M
- IPO Year
- ACRV 2022
- ETON 2018
- Fundamental
- Price
- ACRV $7.87
- ETON $8.40
- Analyst Decision
- ACRV Strong Buy
- ETON Strong Buy
- Analyst Count
- ACRV 5
- ETON 3
- Target Price
- ACRV $22.60
- ETON $10.33
- AVG Volume (30 Days)
- ACRV 103.0K
- ETON 208.5K
- Earning Date
- ACRV 11-07-2024
- ETON 11-07-2024
- Dividend Yield
- ACRV N/A
- ETON N/A
- EPS Growth
- ACRV N/A
- ETON N/A
- EPS
- ACRV N/A
- ETON N/A
- Revenue
- ACRV N/A
- ETON $31,381,000.00
- Revenue This Year
- ACRV N/A
- ETON $19.61
- Revenue Next Year
- ACRV N/A
- ETON $35.39
- P/E Ratio
- ACRV N/A
- ETON N/A
- Revenue Growth
- ACRV N/A
- ETON 8.14
- 52 Week Low
- ACRV $3.19
- ETON $3.03
- 52 Week High
- ACRV $11.90
- ETON $8.64
- Technical
- Relative Strength Index (RSI)
- ACRV 57.76
- ETON 84.76
- Support Level
- ACRV $6.87
- ETON $7.63
- Resistance Level
- ACRV $8.16
- ETON $8.64
- Average True Range (ATR)
- ACRV 0.33
- ETON 0.53
- MACD
- ACRV 0.13
- ETON 0.11
- Stochastic Oscillator
- ACRV 77.86
- ETON 91.78
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.